Owkin Appoints Graeme Bell as Chief Financial Officer
Paris, May 5, 2025 - Owkin, a leading agentic AI company, today announced the appointment of Graeme Bell as Chief Financial Officer (CFO). Graeme brings over 30 years of experience scaling platform-based companies across both private and public markets, having helped raise more than $1.5 billion for emerging growth firms.
Graeme has held CFO roles at leading companies, including Valo Health, Tmunity, Anacor Pharmaceuticals, and Intellia Therapeutics. He also held senior executive positions at Merck & Co. Inc., including Global Head of Investor Relations and U.S. Chief Financial Officer. His background combines deep financial expertise with a strong track record in strategic planning, corporate governance, and operational excellence.
As CFO at Owkin, Graeme will lead global financial strategy and operations, support commercial negotiations, and guide the company’s continued growth as it advances its mission to apply agentic AI’s capability to make the breakthrough discoveries patients urgently need.
“Graeme’s leadership and deep industry expertise will be vital as we scale and enhance our patient impact,”
said Thomas Clozel, co-founder and CEO of Owkin.
“With the launch of our K Navigator agentic AI co-pilot for academics tomorrow, and a pharma-focused product coming soon, Graeme is joining us at a big moment in our journey.”
Graeme Bell, Chief Financial Officer at Owkin, said:
"I am thrilled to be joining Owkin as Chief Financial Officer at such a pivotal moment in the company’s evolution. Owkin's extraordinary mission of using AI to unlock complex biology and deliver improved outcomes for patients resonates deeply with me. What excites me most is the opportunity to work alongside such a talented and driven team to scale the business and expand Owkin's already impressive global impact. I look forward to contributing my experience to support the company’s growth and help deliver on its promise of making a profound difference in the lives of patients worldwide."
Graeme currently advises several emerging biopharma and technology companies and has served on the boards of multiple private firms. He holds an MBA from Durham University and is a Fellow of the Chartered Institute of Management Accountants. In 2023, he was named CFO of the Year by the Boston Business Journal.
Media Contact: michelle.shearly@owkin.com
About Owkin
Owkin is an AI company on a mission to solve the complexity of biology. It is building the first Biology Super Intelligence (BASI) by combining powerful biological large language models, multimodal patient data, and agentic software. At the heart of this system is Owkin K, an AI copilot and its new LLM finetuned on biology called Owkin Zero, used by researchers, clinicians, and drug developers to better understand biology, validate scientific hypotheses, and deliver better diagnostics and therapies faster.
